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Conclusions: Patients with BM-UDP demonstrated comparable survival 
to those with BM-DP. The only prognosticator in our study for BM-UDP 
patients was KPS. Tailored therapeutic strategy with long-term 
palliative intent including WBRT and systemic therapies is reasonable 
for all BM-UDP patients with good performance status.  
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Purpose/Objective: Meningiomas account approximately for 15-20% of 
all primary brain tumours in adults. Neurosurgical resection has been 
considered the first treatment of choice but definitive radiotherapy 
(RT) or postoperative RT for sub-totally resected tumours is an 
integral modality in the treatment of meningiomas. Although short 
term toxicity from RT is uncommon, the potential late RT effects can 
be severe. Radiation treatment planning for Meningiomas can be 
challenging. The ultimate goal is to spare the critical structures while 
delivering the prescribed treatment dose to the target volume. A 
planning comparison was undertaken of both planning techniques to 
establish if there was a dosimetric advantage of VMAT compared with 
3D-CRT with particular reference to dose to PTV coverage and dose to 
normal brain. 
Materials and Methods: 12 patients (8 females, 4 males) with 
Meningioma have been treated over the past 18 months. 60% of 
patients received RT following surgical resection. All patients were 
planned with 3D-CRT and VMAT, optimising dose to tumour. Total dose 
was 50.4Gy in 28 fractions. The GTV was delineated on CT/MRI co-
registered images. A CTV-PTV margin of 0.7cm was added. The 
median treatment volume was 111cc (56-190). Analytical Anisotropic 
Algorithm (AAA) was used to calculate the plans. 
Results: For the PTV, the comparison parameters include mean dose 
and conformation number. Calculation of the conformation number 
(CN) took into account the coverage of the PTV and volume of healthy 
tissue receiving dose above the prescribed dose. 1 is the ideal value. 
Mean PTV dose: 3D-CRT 50.7Gy (range 41.3Gy-54.7Gy) ±4.2 (SD),  
VMAT 50.6Gy (range 50.3Gy-53.9Gy) ±1.3 (SD). 
CN for 3DCRT = 0.446 (range 0.32-0.550) 
VMAT = 0.823 (range 0.70-0.90).  
Absolute improvement in CN in VMAT plans over 3D-CRT was 0.352 
(range 0.206-0.508). 
Normal brain doses :V45 3D-CRT 5.93% (range 3.3%-14.3%), VMAT 
1.41% (range 0.8%-3.8%).  
V10 3D-CRT 38.5% ( range 24.2%-46.9%), VMAT 33.7% (range 24.7%-
55.9%) 
Conclusions: 3D-CRT and VMAT plans achieved equivalent PTV 
coverage. However, VMAT plans achieved superior homogeneity. The 
CN varies considerably leading us to conclude that the PTV coverage 
in the 3D-CRT plans is sub optimal. Although the CN for the VMAT is 
not ideal, it is substantially better. V 45Gy is better in the VMAT plans 
however, V10 is comparable.  
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Purpose/Objective: The aim of the work was to evaluate changes in 
NAA,Cho, lactate and lipid peaks after radiotherapy of partially 
operated gliomas as compared with 1H-MRS data gained before 
radiotherapy. Proton magnetic resonance spectroscopy gives 
information related to cell membrane proliferation, neuronal function 
metabolism and necrotic transformation of brain or tumor tissues. 
Spectroscopy added to MRI helps in tissue characterization of 
intracranial lesions, which could be of help in diagnostic of local brain 
disease. MRS could be helpful in the differentiation of high grade from 
low grade brain tumors, and perhaps in separating recurrence from 
radiation injury. Reduction in the resonance intensity of NAA (N-
acetylaspartate) in the white matter of the brain in MR spectroscopy 
investigations reflects changes in metabolism or axonal density. Active 
demyelization produces changes in the resonance from choline. 
Lactate increases with inflammation due to anaerobic metabolism of 
inflammatory cells,associated mitochondrial dysfunction or occlusion 
of micro vessels. In normal brain NAA produces the highest peak in 
MRS examination. Gliomas malignancy tends to increase with decrease 
in NAA levels. Cho increases at a higher rate with more rapid 
development of neoplasm. Cho is one of the components of membrane 
metabolites and reflects membrane turnover. The presence or 
elevation of lactate and lipid has been attributed to rapid tumor 
growth and necrosis and indicates high tumor grade. Cho peak is 
identified as a marker of tumor cell proliferation. 
Materials and Methods: 52 patients with gliomas with partial 
resection of tumors were subjected to MRI with 1H-MRS examination 
before and after radiotherapy (60 Gy, 2 Gy/day). NAA, Cho, lactate 
and lipid peaks before irradiations were chosen as basic values. 
Results: Changes in peak intensity after radiotherapy depend on the 
malignancy grade of the tumor. Lactate and lipid levels were reduced 
after radiotherapy. NAA level increased. Cho changes were 
unpredictable especially for tumors with high grade of malignancy. 
Changes in NAA, Cho, lipid and lactate peaks could help in evaluation 
of radiotherapy effectiveness and in detection of early recurrence in 
gliomas. 
Conclusions: Changes in peaks intensity after irradiation could be of 
prognostic values. 
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Purpose/Objective: To determine role of irradiation in the treatment 
of patients with advanced Hodgkin’s disease (HD) and bone marrow 
(BM) involvement.  
Materials and Methods: 632 patients (pts) with advanced HD were 
included in this retrospective analysis. In all cases diagnosis of HD 
were confirmed by histology. Extranodal lesions diagnosed in 206 of 
632 pts. Since 1992 whole body BM scintigraphy with 99m??-
nanocolloids visualization is a part of routine staging. All cases of BM 
lesions revealed by scintigraphy were verified by biopsy, additional 
instrumental survey and by follow-up. All pts receive 4-8 cycles of 
chemotherapy with MOPP-ABVor ABVD or BEACOPP. In 45 pts 
visualized BM lesions were irradiated within 20Gy-50Gy (average dose 
38.1Gy). BM lesions were outside radiation fields in another 30 cases. 
Results: In 206 pts with extranodal disease BM invasion revealed in 75 
(36%) cases: 51 pts had one-two BM lesions and another 21 – multifocal 
BM involvement. Overall (OS) and disease free (DFS) 10 year survival 
in pts with BM invasion (49% and 45%) were significantly (p=0,026) 
lower than in other pts with extranodal HD (62% and 65%). In pts with 
only BM involvement and those with BM and other extranodal invasion 
OS and DFS were comparable: 50% versus 47.5% and 48.5 versus 41%. 
On the contrary, OS was significantly different (p=0.014) in pts with 1-
2 BM lesions (57%) and multifocal BM disease (26.5%). Irradiation of BM 
lesions significantly improve 10 year OS (p=0.00005) and DFS (p=0.006) 
in pts with HD: from 16% to 68% and from 23% to 58.5% 
correspondingly. It is especially important that this differences is 
preserved for pts with 1-2 BM foci: 10 year OS and DFS in cases of 
irradiated BM lesions are 72.7% and 57.5% versus 13.5% and 25% - in 
non irradiated BM lesions (p=0.0006 and p=0.054).  
Conclusions:  
1. In pts with advanced HD and BM involvement irradiation of 
visualized BM lesions significantly improve 10 year OS and DFS. 
2. Visualization of BM lesions is of crucial importance for radiotherapy 
planning.  
   
EP-1006   
Methionine-uptake, delivered dose and control of the lesion after 
irradiation of malignant astrocytomas 
T. Iuchi1, K. Hatano2, Y. Uchino3, T. Kodama2, N. Toyama2, T. 
Kawachi2, Y. Hasegawa1, K. Kawasaki1, T. Sakaida1 
1Chiba Cancer Center, Neurological Surgery, Chiba, Japan  
2Chiba Cancer Center, Radiation Oncology, Chiba, Japan  
3Chiba Ryogo Center, Nuclear Medicine, Chiba, Japan  
 
Purpose/Objective: MRIs provide us sufficient information regarding 
the tumor bulk, but a little for the infiltrating tumor cells. For the 
precise planning of the irradiation for infiltrating tumors such as 
gliomas, more biological imagings were required to delineate the 
target, and Methinoine(Met)-PET may be one of the candidates. In this 
study, we evaluated the correlations between Met-uptake before 
irradiation, delivered dose and control of the lesions to elucidate the 
optimal dose to control lesions owing to the Met-uptakes. 
